Cargando…
Anti‐spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents
BACKGROUND: Duration of post‐vaccination protection against COVID‐19 in nursing home (NH) residents is a critical issue. The objective of this study was to estimate the duration of the IgG(S) response to the mRNA BNT162b2 vaccine in NH residents with (COV‐Yes) or without (COV‐No) history of SARS‐CoV...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115082/ https://www.ncbi.nlm.nih.gov/pubmed/35484977 http://dx.doi.org/10.1111/jgs.17837 |
_version_ | 1784709899093016576 |
---|---|
author | Jeulin, Helene Labat, Carlos Duarte, Kevin Toupance, Simon Nadin, Gregoire Craus, Denis Georgiopoulos, Ioannis Gantois, Isabelle Goehringer, François Benetos, Athanase |
author_facet | Jeulin, Helene Labat, Carlos Duarte, Kevin Toupance, Simon Nadin, Gregoire Craus, Denis Georgiopoulos, Ioannis Gantois, Isabelle Goehringer, François Benetos, Athanase |
author_sort | Jeulin, Helene |
collection | PubMed |
description | BACKGROUND: Duration of post‐vaccination protection against COVID‐19 in nursing home (NH) residents is a critical issue. The objective of this study was to estimate the duration of the IgG(S) response to the mRNA BNT162b2 vaccine in NH residents with (COV‐Yes) or without (COV‐No) history of SARS‐CoV‐2 infection. METHODS: A 574 COV‐Yes and COV‐No NH residents were included in 2 cohorts: Main (n = 115, median age 87 years) or Confirmatory (n = 459, median age 89 years). IgG(S) quantification was carried out at three different time points following the BNT162b2 vaccine: three (1st) and seven (2nd) months after the 2nd dose, and 1 month after the 3rd dose (3rd quantification) in the Main cohort, and twice (2nd and 3rd) in the Confirmatory cohort. The seroneutralization capacity according to COVID‐19 history was also measured in a subgroup of patients. RESULTS: Neutralization capacity was strongly correlated with IgG(S) levels (R (2):76%) without any difference between COV‐Yes and COV‐No groups for the same levels of IgG(S). After the 2nd dose, duration of the assumed robust protection (IgG(S) >264 BAU/ml) was two‐fold higher in the COV‐Yes vs. COV‐No group: 12.60 (10.69–14.44) versus 5.76 (3.91–8.64) months, with this advantage mainly due to the higher IgG(S) titers after the 2nd dose and secondary to a slower decay over time. After the 3rd dose, duration of robust protection was estimated at 11.87 (9.88–14.87) (COV‐Yes) and 8.95 (6.85–11.04) (COV‐No) months. These results were similar in both cohorts. CONCLUSIONS AND RELEVANCE: In old subjects living in NH, history of SARS‐CoV‐2 infection provides a clear advantage in the magnitude and duration of high IgG(S) titers following the 2nd dose. Importantly, the 3rd dose induces a much more pronounced IgG(S) response than the 2nd dose in COV‐No subjects, the effect of which should be able to ensure a prolonged protection against severe forms of COVID‐19 in these subjects. |
format | Online Article Text |
id | pubmed-9115082 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91150822022-05-18 Anti‐spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents Jeulin, Helene Labat, Carlos Duarte, Kevin Toupance, Simon Nadin, Gregoire Craus, Denis Georgiopoulos, Ioannis Gantois, Isabelle Goehringer, François Benetos, Athanase J Am Geriatr Soc Clinical Investigations BACKGROUND: Duration of post‐vaccination protection against COVID‐19 in nursing home (NH) residents is a critical issue. The objective of this study was to estimate the duration of the IgG(S) response to the mRNA BNT162b2 vaccine in NH residents with (COV‐Yes) or without (COV‐No) history of SARS‐CoV‐2 infection. METHODS: A 574 COV‐Yes and COV‐No NH residents were included in 2 cohorts: Main (n = 115, median age 87 years) or Confirmatory (n = 459, median age 89 years). IgG(S) quantification was carried out at three different time points following the BNT162b2 vaccine: three (1st) and seven (2nd) months after the 2nd dose, and 1 month after the 3rd dose (3rd quantification) in the Main cohort, and twice (2nd and 3rd) in the Confirmatory cohort. The seroneutralization capacity according to COVID‐19 history was also measured in a subgroup of patients. RESULTS: Neutralization capacity was strongly correlated with IgG(S) levels (R (2):76%) without any difference between COV‐Yes and COV‐No groups for the same levels of IgG(S). After the 2nd dose, duration of the assumed robust protection (IgG(S) >264 BAU/ml) was two‐fold higher in the COV‐Yes vs. COV‐No group: 12.60 (10.69–14.44) versus 5.76 (3.91–8.64) months, with this advantage mainly due to the higher IgG(S) titers after the 2nd dose and secondary to a slower decay over time. After the 3rd dose, duration of robust protection was estimated at 11.87 (9.88–14.87) (COV‐Yes) and 8.95 (6.85–11.04) (COV‐No) months. These results were similar in both cohorts. CONCLUSIONS AND RELEVANCE: In old subjects living in NH, history of SARS‐CoV‐2 infection provides a clear advantage in the magnitude and duration of high IgG(S) titers following the 2nd dose. Importantly, the 3rd dose induces a much more pronounced IgG(S) response than the 2nd dose in COV‐No subjects, the effect of which should be able to ensure a prolonged protection against severe forms of COVID‐19 in these subjects. John Wiley & Sons, Inc. 2022-05-10 /pmc/articles/PMC9115082/ /pubmed/35484977 http://dx.doi.org/10.1111/jgs.17837 Text en Journal of the American Geriatrics Society© 2022 The Authors. Journal of the American Geriatrics Society published by Wiley Periodicals LLC on behalf of The American Geriatrics Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Clinical Investigations Jeulin, Helene Labat, Carlos Duarte, Kevin Toupance, Simon Nadin, Gregoire Craus, Denis Georgiopoulos, Ioannis Gantois, Isabelle Goehringer, François Benetos, Athanase Anti‐spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents |
title | Anti‐spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents |
title_full | Anti‐spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents |
title_fullStr | Anti‐spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents |
title_full_unstemmed | Anti‐spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents |
title_short | Anti‐spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents |
title_sort | anti‐spike igg antibody kinetics following the second and third doses of bnt162b2 vaccine in nursing home residents |
topic | Clinical Investigations |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115082/ https://www.ncbi.nlm.nih.gov/pubmed/35484977 http://dx.doi.org/10.1111/jgs.17837 |
work_keys_str_mv | AT jeulinhelene antispikeiggantibodykineticsfollowingthesecondandthirddosesofbnt162b2vaccineinnursinghomeresidents AT labatcarlos antispikeiggantibodykineticsfollowingthesecondandthirddosesofbnt162b2vaccineinnursinghomeresidents AT duartekevin antispikeiggantibodykineticsfollowingthesecondandthirddosesofbnt162b2vaccineinnursinghomeresidents AT toupancesimon antispikeiggantibodykineticsfollowingthesecondandthirddosesofbnt162b2vaccineinnursinghomeresidents AT nadingregoire antispikeiggantibodykineticsfollowingthesecondandthirddosesofbnt162b2vaccineinnursinghomeresidents AT crausdenis antispikeiggantibodykineticsfollowingthesecondandthirddosesofbnt162b2vaccineinnursinghomeresidents AT georgiopoulosioannis antispikeiggantibodykineticsfollowingthesecondandthirddosesofbnt162b2vaccineinnursinghomeresidents AT gantoisisabelle antispikeiggantibodykineticsfollowingthesecondandthirddosesofbnt162b2vaccineinnursinghomeresidents AT goehringerfrancois antispikeiggantibodykineticsfollowingthesecondandthirddosesofbnt162b2vaccineinnursinghomeresidents AT benetosathanase antispikeiggantibodykineticsfollowingthesecondandthirddosesofbnt162b2vaccineinnursinghomeresidents |